Can a new tracer light up cancer growth?

NCT ID NCT00935090

Ongoing Diagnosis Sponsor: Barbara Ann Karmanos Cancer Institute Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and diagnose cancer, and possibly predict how well a patient might respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A radioactive tracer called FLT, injected into the vein, used with a PET scan to measure tumor growth.
What this could lead to: If successful, this imaging method could help doctors detect cancer more accurately and plan better treatments.
What could go wrong: This is an early-phase trial, so the tracer may not work as hoped or may not be widely available. There are also risks from radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera acute biphenotypic leukemia acute myeloid leukemia anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma B-cell chronic lymphocytic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive Burkitt lymphoma cancer central nervous system cancer chronic eosinophilic leukemia chronic myelomonocytic leukemia chronic neutrophilic leukemia Congenital Abnormalities diffuse large B-cell lymphoma essential thrombocythemia follicular lymphoma hairy cell leukemia hematopoietic and lymphoid cell neoplasm Hodgkins lymphoma Immunoglobulin Light-chain Amyloidosis intraocular lymphoma large-cell immunoblastic lymphoma leukemia Leukemia, Large Granular Lymphocytic leukemia, myeloid, accelerated-phase Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Leukemia, Myeloid, Chronic-Phase lymphoma Lymphoma, B-Cell, Marginal Zone Lymphoma, Extranodal NK-T-Cell lymphoproliferative syndrome mantle cell lymphoma mast cell leukemia mycosis fungoides myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative disease myelodysplastic/myeloproliferative neoplasm Myeloproliferative Disorders myeloproliferative neoplasm neoplasm non-Hodgkin lymphoma plasma cell myeloma plasma cell neoplasm Precursor Cell Lymphoblastic Leukemia-Lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma primary cutaneous T-cell non-Hodgkin lymphoma primary myelofibrosis prolymphocytic leukemia Sezary syndrome Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS CHRONIC MYELOPROLIFERATIVE DISORDERS LEUKEMIA LYMPHOMA LYMPHOPROLIFERATIVE DISORDER MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM MYELODYSPLASTIC SYNDROMES MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201-1379, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.